| Abstract | Photoradiation therapy (PRT) is a new technique that is currently under investigation for the treatment of a variety of solid malignant tumors. The technique involves systemic administration of hematoporphyrin derivative (HpD), a photosensitizing compound that is preferentially retained by malignant cells and photoactivation of the neoplasm with red light (630 nm) to achieve selective destruction of cancer cells. We used HpD PRT for seven patients with malignant melanoma of the uvea and conclude that initial results of HpD PRT for uveal malignant melanoma are encouraging and justify further investigation. |
| Authors | D T Tse, J J Dutton, T A Weingeist, V M Hermsen, R C Kersten |
| Journal | Archives of ophthalmology
(Arch Ophthalmol)
Vol. 102
Issue 6
Pg. 833-8
(Jun 1984)
ISSN: 0003-9950 UNITED STATES |
| PMID | 6233958
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
| Chemical References |
- Hematoporphyrins
- Radiation-Sensitizing Agents
- Hematoporphyrin Derivative
- Xenon
|
| Topics |
- Eye Neoplasms
(drug therapy)
- Female
- Hematoporphyrin Derivative
- Hematoporphyrins
(adverse effects, therapeutic use)
- Humans
- Laser Therapy
- Male
- Melanoma
(drug therapy)
- Orbital Neoplasms
(drug therapy)
- Photochemotherapy
(adverse effects)
- Radiation-Sensitizing Agents
(therapeutic use)
- Xenon
(therapeutic use)
|
